These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 37914171)

  • 1. Pembrolizumab-induced immune-related sclerosing cholangitis.
    Li Y; Stewart L; Tang S; McWhirter E
    BMJ Case Rep; 2023 Nov; 16(11):. PubMed ID: 37914171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abdominal pain accompanied by elevated serum inflammatory markers and biliary enzymes for diagnosing immune checkpoint inhibitor-induced sclerosing cholangitis.
    Yamamoto T; Mizuno K; Ito T; Yokoyama S; Yamamoto K; Imai N; Ishizu Y; Honda T; Ishikawa T; Kanamori A; Yasuda S; Toyoda H; Yokota K; Hase T; Nishio N; Maeda O; Ishii M; Sone M; Ando Y; Akiyama M; Ishigami M; Kawashima H
    Invest New Drugs; 2023 Jun; 41(3):512-521. PubMed ID: 37171720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pembrolizumab-induced sclerosing cholangitis in a lung adenocarcinoma patient with a remarkable response to chemotherapy: a case report.
    Sato K; Hayashi M; Abe K; Fujita M; Takahashi A; Ohira H
    Clin J Gastroenterol; 2020 Dec; 13(6):1310-1314. PubMed ID: 32643124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A case report on severe nivolumab-induced adverse events similar to primary sclerosing cholangitis refractory to immunosuppressive therapy.
    Hirasawa Y; Yoshimura K; Matsui H; Kubota Y; Ishida H; Arai J; Sakaki M; Oguro N; Shida M; Taniguchi M; Hamada K; Ariizumi H; Ishiguro T; Ohkuma R; Sambe T; Horiike A; Imamura CK; Shiozawa E; Wada S; Tsurutani J; Iwamoto S; Uchida N; Kiuchi Y; Tate G; Kobayashi S; Tsunoda T
    Medicine (Baltimore); 2021 Jun; 100(23):e25774. PubMed ID: 34114983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report.
    Hines J; Daily E; Pham AK; Shea CR; Nadeem U; Husain AN; Stadler WM; Reid P
    J Med Case Rep; 2021 Mar; 15(1):124. PubMed ID: 33736690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab Induced Sclerosing Cholangitis: Why You Need a Liver Biopsy.
    Liang I; Chu G; Zielinski R
    Case Rep Oncol; 2023; 16(1):182-187. PubMed ID: 37013108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report.
    Nabeshima S; Yamasaki M; Matsumoto N; Takaki S; Nishi Y; Kawamoto K; Taniwaki M; Ohashi N; Hattori N
    Cancer Treat Res Commun; 2021; 26():100270. PubMed ID: 33338849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis.
    Takinami M; Ono A; Kawabata T; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Kenmotsu H; Naito T; Murakami H; Endo M; Kiyohara Y; Yasui H; Niwakawa M; Takahashi T
    Invest New Drugs; 2021 Dec; 39(6):1716-1723. PubMed ID: 34046801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resolution of radiographic abnormalities with ursodeoxycholic acid therapy of primary sclerosing cholangitis.
    Lebovics E; Salama M; Elhosseiny A; Rosenthal WS
    Gastroenterology; 1992 Jun; 102(6):2143-7. PubMed ID: 1587436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.
    Eggermont AMM; Kicinski M; Blank CU; Mandala M; Long GV; Atkinson V; Dalle S; Haydon A; Khattak A; Carlino MS; Sandhu S; Larkin J; Puig S; Ascierto PA; Rutkowski P; Schadendorf D; Koornstra R; Hernandez-Aya L; Di Giacomo AM; van den Eertwegh AJM; Grob JJ; Gutzmer R; Jamal R; Lorigan PC; Krepler C; Ibrahim N; Marreaud S; van Akkooi A; Robert C; Suciu S
    JAMA Oncol; 2020 Apr; 6(4):519-527. PubMed ID: 31895407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine.
    Kozaiwa K; Tajiri H; Sawada A; Tada K; Etani Y; Miki K; Okada S
    J Gastroenterol Hepatol; 1998 Aug; 13(8):825-9. PubMed ID: 9736177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
    Sterling RK; Salvatori JJ; Luketic VA; Sanyal AJ; Fulcher AS; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
    Aliment Pharmacol Ther; 2004 Nov; 20(9):943-9. PubMed ID: 15521841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of Ursodeoxycholic Acid in the Treatment of Primary Sclerosing Cholangitis with Ulcerative Colitis: A Pediatric Case.
    Fujita Y; Sugaya T; Inui A; Yoshihara S
    Tohoku J Exp Med; 2021 Feb; 253(2):109-112. PubMed ID: 33551380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series.
    Schramm C; Schirmacher P; Helmreich-Becker I; Gerken G; zum Büschenfelde KH; Lohse AW
    Ann Intern Med; 1999 Dec; 131(12):943-6. PubMed ID: 10610645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
    Stiehl A
    Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab-related cholangitis with multiple fatal liver abscesses after endoscopic biliary drainage: a case report and review of the literature.
    Hori H; Fujita K; Nishio A; Nishijima M; Inaba M; Anami T; Matsui S; Kitamura Y; Matsuoka R; Watanabe A
    Clin J Gastroenterol; 2022 Apr; 15(2):475-479. PubMed ID: 35072901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses.
    van Hoogstraten HJ; Wolfhagen FH; van de Meeberg PC; Kuiper H; Nix GA; Becx MC; Hoek AC; van Houte DP; Rijk MC; Salemans JM; Scherpenisse J; Schrijver M; Smit AM; Spoelstra P; Stadhouders PH; Tan TG; Hop WC; ten Kate FJ; vanBerge-Henegouwen GP; Schalm SW; van Buuren HR
    J Hepatol; 1998 Sep; 29(3):417-23. PubMed ID: 9764988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A case of pembrolizumab-induced sclerosing cholangitis that was responsive to high-dose steroid therapy].
    Nagasawa S; Miyazaki M; Morita Y; Tanaka K; Yada M; Masumoto A; Motomura K
    Nihon Shokakibyo Gakkai Zasshi; 2021; 118(10):981-990. PubMed ID: 34629349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulcerative colitis complicated by primary sclerosing cholangitis and autoimmune hepatitis overlap syndrome: a case report and literature review.
    Zhang X; Lin X; Li X; Guan L; Li Y; Wang N
    Front Immunol; 2023; 14():1132072. PubMed ID: 37228618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.